Osteoporosis treatment: why ibandronic acid?

Abstract

Pivotal studies on ibandronic acid efficacy in terms of antifracture effects on nonvertebral fractures had some intrinsic limitations. However, a large body of indirect evidence suggests that ibandronate has significantly sustained vertebral and nonvertebral antifracture efficacies in women with postmenopausal osteoporosis, in comparison to those observed with other nitrogen-containing bisphosphonates. Discrepancies in efficacy between the available bisphosphonate regimens appear to be a function of dose rather than to inherent differences in their respective therapeutic potential. Drugs or treatment regimens that minimize the risk of osteoporotic fractures and make the treatment of osteoporosis more convenient and suitable for patients are preferred: ibandronic acid marketed at oral doses of 150 mg once monthly and 3 mg quarterly as intravenous injection has these characteristics. The safety profile of ibandronic acid treatment appears to be good overall and in some cases better than that of other nitrogen-containing bisphosphonates.

Ibandronate for the prevention of bone loss after allogeneic stem cell transplantation for hematologic malignancies: a randomized-controlled trial

“…bisphosphonates such as zoledronic acid. 24,[26][27][28][29] Thus, ibandronate may be a viable option in preventing bone loss especially in patients with pre-existing renal damage or those who develop renal insufficiency during the course of their allo-SCT. Furthermore, this trial evaluated doses used to treat post-menopausal osteoporosis and using higher doses in our patient population may need to be evaluated.…”

“…Medications that are convenient to administer are preferred and ibandronate has these characteristics. 24 In addition, since all patients who have undergone allo-SCT experience bone loss, all patients should receive standard recommendations of calcium and vitamin D supplementation. Additional studies evaluating the effectiveness of pharmacological agents with different mechanisms of action to prevent and treat bone loss with the least amount of side effects are warranted.…”

“…ibandronate from several studies, none of which were designed to evaluate the risk of non-vertebral fracture, concluded that ibandronate has sustained vertebral an non-vertebral anti fracture efficacy. 24 To our knowledge, ibandronate has not been studied for the prevention of bone loss after allo-SCT in a randomized fashion. We conducted a prospective randomized placebo-controlled trial to study the effects of treatment with ibandronate on BMD changes following allo-SCT.…”

“…[21][22][23] There have been some controversies about the effects of ibandronate on non-vertebral fractures in the literature. A post hoc analysis conducted by Rossini et al 24 by combining various doses of oral and i.v. ibandronate from several studies, none of which were designed to evaluate the risk of non-vertebral fracture, concluded that ibandronate has sustained vertebral an non-vertebral anti fracture efficacy.…”

RATsIONAL'NYY VYBOR FARMAKOTERAPII POSTMENOPAUZAL'NOGO OSTEOPOROZA.EFFEKTIVNOST' I BEZOPASNOST' BONVIVY: OBZOR ZA VOSEM' LET PRIMENENIYa

“…В ряде случаев нежелательные явления можно объяснить несоблю-дением инструкций применения бФ, сопутствующей пато-логией ЖКТ или просто страхом побочных эффектов [81,82]. В клинических исследованиях ибандроната не было статистически значимых различий в частоте нежелательных явлений со стороны верхних отделов ЖКТ между группой лечения и плацебо [10].…”